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a  b  s  t  r  a  c  t
Androgen  receptor  (AR) is the  main  target  for prostate  cancer  therapy.  Clinical  approaches  for  AR  inacti-
vation  include  chemical  castration,  inhibition  of androgen  synthesis  and  AR  antagonists  (anti-androgens).
However,  treatment  resistance  occurs  for  which  an  important  number  of  therapy  escape  mechanisms
have  been  identiﬁed.  Herein,  we  summarise  the current  knowledge  of  molecular  mechanisms  underlying
therapy  resistance  in prostate  cancer.  Moreover,  the  tumour  escape  mechanisms  are  arranged  into  theeywords:
R-targeting therapies
herapy resistance mechanisms
arget modiﬁcation
ypass signalling
istologic transformation
concepts  of  target  modiﬁcation,  bypass  signalling,  histologic  transformation,  cancer  stem  cells  and  mis-
cellaneous  mechanisms.  This  may  help  researchers  to  compare  and  understand  same  or similar  concepts
of therapy  resistance  in  prostate  cancer  and other  cancer  types.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).ancer stem cells
. Introduction
.1. Prostate tissue architecture
The prostate is an exocrine gland of the male reproduc-
ive system surrounding the prostatic urethra [1] and composed
f acini, which are formed by a pseudo-stratiﬁed columnar
pithelium comprising a terminally differentiated, secretory layer
nd a less differentiated basal compartment with regenerating
ells [2]. A basement membrane separates the epithelial cells
rom the surrounding ﬁbro-muscular stroma. Within the secre-
ory layer, neuroendocrine cells represent a rare lineage, lack
xpression of androgen receptor (AR) and are thus not growth-
ependent on androgens [3]. However, the prevalent lineage
onsists of AR-positive, luminal cells whose secretome is rich
n prostate acid phosphatase (ACPP), kallikrein-related peptidase
 (KLK3; also known as prostate speciﬁc antigen, PSA) and -
icroseminoprotein (MSMB) [4].
Adult tissue stem cells (SC) reside within the basal layer and
re able to regenerate the prostate through a differentiation pro-
ess into secretory cells [2]. SC with a high expression of prominin
 (PROM1) and integrin 2 (ITGA2) give rise to rapidly proliferat-
ng, transit amplifying cells (PROM1−, ITGA2hi), which can further
∗ Corresponding author. Tel.: +43 0 512 504 81801; fax: +43 0 512 504 24817.
E-mail address: frederic.santer@i-med.ac.at (F.R. Santer).
ttp://dx.doi.org/10.1016/j.semcancer.2015.08.005
044-579X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article udifferentiate into committed basal cells (PROM1−, ITGA2lo) with a
slower cell cycle. In vitro terminal differentiation of basal cells to
a luminal phenotype is mainly triggered by androgens [5]. Addi-
tionally, basal cells can be differentiated into neuroendocrine cells
in vitro [6].
1.2. Prostate cancer: Treatment options
The vast majority of all prostate cancer (PCa) cases are aci-
nar adenocarcinomas and histologically appear as hyperplasia of
luminal cells. Deferred treatment, radical prostatectomy, androgen
deprivation therapy (ADT) and external beam radiation therapy are
current options for localised PCa [7]. At a metastatic stage (M1),
the disease becomes incurable and the mean survival is 21–54
months, depending on the treatment response [7]. A common
ﬁrst-line therapy option at this stage of the disease is androgen
deprivation therapy (ADT), based on initial ﬁndings by Hug-
gins and Hodges [8] helping to understand that PCa growth and
progression is dependent on androgens. AR inactivation can be
accomplished by several means. Surgical castration (orchiectomy)
is only rarely performed these days. Chemical castration can be
achieved by interfering with the hormonal signalling pathway of
the hypothalamic–pituitary–gonadal axis, which regulates the pro-
duction of testosterone. This consequently leads to hypogonadism
with castrate testosterone levels below 20 ng/dl (1 nmol/l). Com-
plete androgen blockade (CAB) can be reached in combination with
chemical castration by the use of non-steroidal anti-androgens (e.g.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ydroxyﬂutamide, bicalutamide) that compete with the natural
igand dihydrotestosterone (DHT) for binding to the AR.
Recurrence after ADT/CAB is termed castration-resistant
rostate cancer (CRPCa) and is concurrent with a reactivation of the
R signalling axis. Treatment options at this stage of the disease
nclude taxane-based chemotherapy, dendritic cell vaccination-
ased immunotherapy, the calcium mimic 223Radium dichloride
argeting bone metastases, and second-generation AR-targeting
herapies [9,10]. However, resistance to therapy invariably occurs
t these advanced stages of the disease, including ab initio resis-
ance and/or cross-resistance to previously used drugs [11,12].
.3. AR: Main target in PCa therapy
Luminal cells are essentially dependent on androgens for
urvival, or more precisely, dependent on active AR signalling. Inac-
ivation of this signalling axis is the primary goal of ADT, CAB
nd second-generation agents enzalutamide and abiraterone. It is
herefore not surprising that in the past most work elucidating
esistance mechanisms against this therapy was focused on the AR
ignalling axis.
The gene encoding AR on Xq12 is organised into 8 exons [13]
nd structurally belongs to the nuclear steroid hormone receptor
amily. Exon 1 encodes the aminoterminal domain (NTD) and con-
ains activation function 1 (AF-1; transcriptional units (TAU)-1 and
5). The DNA binding region consists of two zinc ﬁnger motifs, is
ncoded by exons 2 and 3, and is responsible for binding to andro-
en response elements (ARE) in promoter and enhancer regions of
arget genes. It is followed by a hinge region where a nuclear local-
sation signal is located, that is sterically unmasked upon ligand
inding. Exons 4–8 comprise the ligand binding domain (LBD), as
ell as AF-2, which has only minor transcriptional activity [14]. AR
nteracts with an important number of co-integrators via the LXXLL
otifs in the amino- and carboxy-terminal domains, controlling the
ull transcriptional activity/repression of AR [15].
The present review will summarise known therapeutic resis-
ance mechanisms in the secretory and the basal prostatic layer and
lassify the therapy escape routes in the categories target modiﬁca-
ion, bypass signalling pathways, histologic transformation, cancer
tem cells and miscellaneous mechanisms. This categorisation of
umour escape mechanisms has been adapted for PCa according
o a recent publication based on resistance mechanisms to kinase
nhibitors [16].
. Target modiﬁcation
.1. Target overexpression and hypersensitive pathway
The most common molecular mechanism of endocrine therapy
esistance is ampliﬁcation of the AR gene locus. A number of
tudies have analysed paired patient biopsies before therapy, and
fter acquisition of castration resistance [17,18]. Ampliﬁcation
f the Xq12 locus, but also X-chromosome polysomy, have been
ocumented in about 30% of all patients progressing to CRPCa,
ut were absent in the hormone-naïve specimens. These multiple
opies of the AR gene result in high expression of AR mRNA
nd protein [18,19]. In vitro studies showed that AR transcrip-
ional activity is regulated not only by the expression levels of both
igand and the receptor [20], but also as a consequence of increased
eceptor binding to chromatin [21]. In other words, ADT causes an
mpliﬁcation of the AR locus, in which a disturbed ratio of AR and
ts ligand results in a hypersensitive AR signalling pathway. Cells
ith such a high AR expression can deal with the low androgen
oncentrations during ADT, and give rise to new clonal outgrowth
f castration resistant cells. However, AR gene ampliﬁcation mightr Biology 35 (2015) 133–144
not be exclusively driven by ADT. A recent study discovered an
ampliﬁcation of the AR locus in small foci of cells in hormone-naïve
patients suggesting that ADT could select for the clonal expansion
of an already existing ab initio resistant cell population [22]. Of
clinical interest is the fact that patients with AR ampliﬁcation
and thus high AR levels could take advantage of a CAB approach,
inhibiting AR directly instead of following a standard ADT protocol
only [23]. Interesting to note is that selection of patients for this
purpose could be done on the detection of AR ampliﬁcations in
circulating tumour cells isolated from the patients’ blood, thereby
possibly eliminating the need for biopsies [24].
Another mechanism leading to a highly expressed and hyper-
sensitive AR pathway is the stabilisation of AR, i.e. a longer half-life
of the protein through decreased degradation or through increased
translation. The Cullin-based E3 ligase SPOP can promote poly-
ubiquitination and subsequent proteasomal degradation of AR,
as well as of its co-activator NCOA3 [25,26]. Mutations in the
substrate-binding cleft of SPOP impair ubiquitination of AR and
NCOA3, thereby extending the turnover and leading to an accu-
mulation of these proteins. PCa-speciﬁc mutations of SPOP are
found in up to 15% of analysed specimens [27]. However, the fre-
quency of SPOP mutations (3 out of 50 cases) seems to be lower
in CRPCa [28], raising the question whether this mechanism con-
tributes to castration resistance. Another E3 ligase, SIAH2, was
found increasingly expressed in CRPCa and to selectively regulate
the transcriptional activity of AR [29]. MID1, which is known to
interact with active polyribosomes, has been shown to associate
with AR mRNA [30]. Negative regulation by the AR signalling axis
leads to high MID1 expression under androgen deprived conditions,
favouring increased AR translation and expression. Usually, AR is
a negative regulator of its own  transcription under normal andro-
gen concentrations [31]. However, the castrate androgen levels in
CRPCa are sufﬁcient to stimulate AR activity on enhancer elements,
but not suppressor elements, resulting in an increased expression
of AR and AR-repressed genes, which may  drive progression to
CRPCa [32]. In conclusion, multiple mechanisms can eventually
result in high expression levels of AR, which are transcriptionally
hypersensitive to the residual amounts of DHT in castrate patients
(Fig. 1a).
2.2. Target mutation and promiscuous pathway
Base substitutions in the coding sequence of the AR gene are
less frequently observed than ampliﬁcations of the locus. The lat-
est study using exome sequencing revealed a mutation frequency
of 10% in CRPCa specimens (n = 50) [28]. Clinically relevant muta-
tions occur in the ligand-binding pocket [33]. For instance, a recent
study discovered H874Y and T877A mutations in circulating cell-
free DNA from patients that no longer responded to treatment
with abiraterone, and a F876L amino acid substitution in one
enzalutamide-resistant patient [34]. The latter mutation, F876L,
was found in earlier experimental approaches to confer resistance
to enzalutamide and ARN-509, an anti-androgen undergoing clini-
cal trials [35,36]. The T877A mutation can also be detected in CRPCa
patients that progressed on abiraterone treatment [37]. The driv-
ing force for the occurrence of many AR mutations in the LBD
is broadened ligand speciﬁcity. Promiscuous activation of mutant
AR by adrenal androgens, progesterone, cortisol and cortisone,
-estradiol, testosterone metabolites, and moreover, the anti-
androgens hydroxyﬂutamide, bicalutamide and enzalutamide has
been documented [36,38–43]. These agonistic properties of the AR
antagonists may  be the basis of the anti-androgen withdrawal syn-
drome described for all three drugs [44–46]. Furthermore, T877A
generates an androgen-independent gain of function for nuclear
import [47] and H874Y enhances binding to the co-activators
NCOA1-3 [48]. Thus, base substitutions in the AR can be responsi-
F.R. Santer et al. / Seminars in Cancer Biology 35 (2015) 133–144 135
Fig. 1. Molecular mechanisms of AR-targeting therapy escape. Several molecular mechanisms leading to a reactivation of the AR-signalling axis and a progression to CRPCa
have  been described. These can be grouped in target modiﬁcation (overexpression/hypersensitivity (a); target mutation/promiscuous (b); truncated AR variants/constitutively
active  (c)) and bypass (AR transactivation/outlaw (d); co-regulator alterations (e), altered androgenesis (f), alternative steroid receptors (g)) pathways. ADT, androgen
deprivation therapy; T, testosterone; DHT, dihydrotestosterone; Bic, bicalutamide; Prog, progesterone.
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tle for a reactivation of the AR signalling axis, through alternative
teroidal and non-steroidal ligands under conditions where DHT is
estricted (Fig. 1b).
.3. Truncated AR variants and constitutively active pathway
C-terminal truncated AR variants may  arise through proteolytic
leavage of full length AR, AR gene rearrangement, and by alter-
ative splicing of the AR gene transcript [49–52]. To date, around
0 AR variants have been documented, which lack the LBD render-
ng these variants constitutively active even in the absence of its
igand [53]. Although there are conﬂicting reports whether AR vari-
nts require dimerisation with the full length receptor for nuclear
mport and transcriptional activity [54,55], there is consensus that
esistance against the currently available therapies targeting the
BD of AR can be mediated by truncated AR variants [56,57]. The
est investigated AR variant, AR-V7, can be increasingly detected in
RPCa tissues using AR-V7 speciﬁc antibodies [58,59]. Its expres-
ion is induced by ADT and predicts progression to CRPCa [60].
urthermore, AR-V7 mRNA expression in circulating tumour cells
orrelates with primary resistance to abiraterone and enzalutamide
61]. These AR variants may  induce a distinct gene expression signa-
ure compared to the full length receptor [62]. The transcriptional
rogram of AR-Vs preferentially leads to expression of cell cycle
egulatory genes, while full length AR represses that program and
avours transcription of genes related to macromolecular synthesis,
etabolism and differentiation. The recognition that LBD-deﬁcient
R variants drive CRPCa has prompted the development of anti-
ndrogens targeting the NTD of AR, which possesses the highest
ranscriptional activity [14]. In conclusion, truncated AR variants
re constitutively active and can promote AR signalling without
he need for a ligand (Fig. 1c).3. Bypass signalling pathways
3.1. AR transactivation and outlaw pathway
Several studies show that AR can also be transactivated by
growth factors, neuropeptides and cytokines. For instance, IL6 can
cross-talk to the AR signalling axis and lead to the transcription of
KLK3 under castrate androgen conditions [63]. AR transactivation
in response to IL6 can be mediated by MAPK and STAT3 pathways,
whereas signalling through PI3K-Akt suppresses this interaction
[64]. Interestingly, STAT3 is able to heterodimerise with the N-
terminal domain of AR upon IL6 signalling in LNCaP cells [65].
Activation of the MAPK pathway by IL6 leads to phosphorylation of
the AR co-activator NCOA1 thereby enhancing AR transcriptional
activity [66]. In addition, the kinase FER may  phosphorylate AR at
tyrosine 223 and participate in the crosstalk with AR in response
to IL6/STAT3 signalling [67]. The IL6 transactivating effects on AR
can be reversed by MAPK inhibition or with the anti-androgen bica-
lutamide [68]. Another example is the tyrosine kinase SRC which
can phosphorylate AR thereby regulating AR’s nuclear transloca-
tion, chromatin recruitment and transcriptional activity [69]. SRC
is known to play important roles in the progression and recur-
rence of a number of cancer types [70]. SRC plays also a role in
AR transactivation by the neuropeptide bombesin and promotes an
overlapping but not identical AR transcriptional program [71]. Ear-
lier it was shown that EGF, keratinocyte growth factor (KGF) and
insulin-like growth factor-1 (IGF1) are also able to transactivate
AR in the absence of androgens, which, like IL6 can be blocked by
bicalutamide treatment [72]. In conclusion, several signalling path-
ways can cause transactivation of AR in the absence of its ligand
or under low androgen concentrations and thus contribute to PCa
progression (Fig. 1d).
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.2. Co-regulator alterations and aberrant transcription
AR transcriptional activity is controlled by numerous co-
egulators, i.e. co-activators and co-repressors [15]. Aberrant
xpression of co-regulators has been associated with PCa progres-
ion, and in addition the expression of various co-regulators is
irectly regulated through androgenic action [73]. For instance,
ncreased expression of the histone (lysine) acetyltransferase (HAT)
P300 has been detected in PCa cells after androgen deprivation
74]. EP300 is involved in transactivation of the AR through IL6
75]. Moreover, bombesin is able to activate EP300 HAT activity
ia SRC and PRKCD pathways. This results in AR protein acetylation
nd an increased expression of AR-regulated genes [76]. A similar
ole has been documented for the close EP300 homologue CREB-
inding protein (CREBBP), which is also increased after androgen
ithdrawal [77]. Protein kinase A (PKA), which is frequently over-
xpressed in PCa, leads to the transcription of AR regulated genes
n response to cAMP [78]. This involves the phosphorylation of
AMP responsive element-binding protein (CREB) through PKA and
he recruitment of EP300 and CREBBP. In cells with a high expres-
ion of CREBBP and EP300, the co-activators may  act as a bridging
olecule between AR and CREB, resulting in an enhanceosome-
ased cooperation [79]. Interestingly, PKA can also phosphorylate
nd enhance nuclear translocation and repressive function of the
uclear receptor co-repressor NCOR1 [80]. Although this would
sually favour AR transcriptional inactivation, the situation may  be
ifferent in a particular cellular context; exogenous overexpression
f NCOR1 and NCOR2 can increase AR transcriptional activity, pos-
ibly due to an impaired AR/co-repressor interaction [81]. Another
tudy found altered recruitment to AR but also loss of expres-
ion of NCOR1/2 in CWR22R castration-resistant cells compared to
he androgen-dependent CWR22 [82]. BAG1 is an AR co-regulator
hose expression levels are also increased in CRPCa [83]. Ampli-
cation of its locus was found in 7.4% of CRPCa samples, while
nalysis of treatment-naïve samples did not reveal gene aberra-
ions. BAG1 binds to a novel identiﬁed sequence adjacent to the
F-2 of AR, termed binding function 3 (BF-3) [84]. BAG1 is impor-
ant for ﬁne-tuning AR transcriptional activity and for suppressing a
ub-set of AR responsive genes. In conclusion, the changed expres-
ion proﬁle of AR co-regulators caused by ADT has implications for
he transcriptional activity and program of AR and can result in an
berrant expression of AR downstream genes promoting survival
f the malignant cells (Fig. 1e).
.3. Altered androgenic pathways
AKR1C3 encodes for an aldo–keto reductase that converts
ndrostenedione, a weak adrenal androgen, into testosterone [85].
his steroidogenic enzyme, among others of androgen metabolism,
as increasingly detected in mCRPCa bone samples compared to
rimary treatment-naïve PCa [86]. In other words, intra-tumoural
pregulation of androgenic enzymes enables conversion of adrenal
teroids into testosterone and DHT with levels that are sufﬁcient
o activate transcription through AR and drive castration resis-
ance (also known as the front-door, conventional pathway, Fig. 1f)
87,88]. Interestingly, this intra-tumoural conversion of adrenal
teroids is not only a mechanism of resistance against ADT; upre-
ulation of AKR1C3 was also found in cells that are resistant to
he second-line anti-androgen enzalutamide [89]. A recent study
as shown that the transcription factor ERG, which is fused to the
ndrogen-responsive TMPRSS2 in about 50% of PCa patients [90],
s a direct positive regulator on the AKR1C3 promoter [91]. ERG
s co-expressed with AKR1C3 in PCa tissue samples. This could
ave clinical implications and explain why TMPRSS2-ERG in cir-
ulating tumour cells is a predictive biomarker of sensitivity for
RPCa patients treated with the CYP17A1 inhibitor abirateroner Biology 35 (2015) 133–144
acetate, which inhibits the formation of adrenal androgens [92].
Studies with a newly developed AKR1C3 inhibitor, SN33638, have
been conducted in cell culture models [93]. However, the authors
conclude that only a subset of CRPCa patients with high AKR1C3
expression could possibly beneﬁt from such a therapy. Other
steroidogenic enzymes may  also be implicated in progression to
CRPCa. A gain-of-function mutation in the HSD3B1 enzyme has
been discovered in some CRPCa tissue specimens, which controls
the rate-limiting step from dehydroepiandrosterone into DHT [94].
This mutation renders the enzyme resistant to ubiquitin-mediated
proteasomal degradation, leading to its accumulation and acceler-
ated synthesis of DHT. The expression levels and isozyme activity
of 5-steroid reductase, which converts testosterone into DHT,
is shifted from isoform 2 (SRD5A2) to isoform 1 (SRD5A1) and 3
(SRD5A3) in CRPCa [95,96]. The mineralocorticoid deoxycorticos-
terone is also reduced by SRD5A1 and is able to activate the AR [97].
5-Dehydro-deoxycorticosterone was detected in eight out of 13
CRPCa tissues.
Another alternative steroidogenic route resulting from high
expression and activity of SRD5A1 and AKR1C3 involves the con-
version of androstenedione to 5-androstanedione, and ﬁnally into
DHT. This pathway bypasses the formation of testosterone (5-
androstanedione pathway). The shift from SRD5A2 to the SRD5A1
isoform in CRPCa samples may  be a consequence of the fact that
SRD5A1 has much higher afﬁnity for androstenedione compared to
SRD5A2 [98]. This pathway was shown to be the dominant pathway
in CRPCa cell line models and metastatic tissue samples.
DHT may  also be synthesised from cholesterol via the
metabolites progesterone, allopregnanolone, androsterone and
androstanediol, again by circumventing testosterone (back-door
pathway) [99]. DHT synthesis through the back-door pathway
requires the enzymes CYP17A1 and SRD5A, as well as a reverse
oxidative step of androstanediol to DHT [100]. However, expres-
sion of CYP17A1 in PCa tissues seems to be low and infrequent
[101,102], raising the question whether this back-door pathway
actually plays a role in the acquisition of castration resistance.
3.4. Alternative steroid receptors
Glucocorticoids are frequently co-administered with abi-
raterone in order to counteract the drug-induced reductions in
serum cortisol levels [103]. The glucocorticoid receptor (GR) how-
ever has been shown to drive a set of certain AR gene targets,
including KLK3, in the absence of AR [104]. GR expression is
increased in several PCa cell lines treated with the anti-androgens
ﬂutamide, bicalutamide and enzalutamide, and GR expression in
metastatic tissue specimens isolated from the bone marrow cor-
relates with the patients’ response to enzalutamide [104,105]. A
recent study demonstrated that GR transcriptional expression is
inhibited through AR signalling via a negative androgen response
element [106]. Thus, activation of the GR under conditions where
AR is inactivated may  give PCa cells a survival beneﬁt and drive
progression to castration resistance. Furthermore, a role for GR
as a negative prognostic factor has already been described in ER-
negative breast cancer [107]. This shows that steroid receptors may
be able to compensate for the inactivation of another steroid recep-
tor and thereby promote survival of the cell (Fig. 1g).
4. Histologic transformation
4.1. Neuroendocrine (trans-)differentiationAs stated above, neuroendocrine cells are rare secretory
cells in normal prostatic tissue. Variable numbers of neuroen-
docrine cells can be detected in prostate adenocarcinomas by
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mmunohistochemical analysis, in part depending on the number
f slides and various neuroendocrine antigen markers that are
sed [108]. The clinical prognostic signiﬁcance of the presence
nd percentage of neuroendocrine cells in tumour specimens is
nclear, although high grade and stage cancers express higher
evels of chromogranin A (CHGA) than low grade or localised dis-
ase [109]. In contrast, there is no doubt that growth of malignant
euroendocrine-like cells is favoured by androgen deprivation and
ssociated with acquisition of castration resistance, as well as loss
f AR expression in a subset of CRPCa tissues [110,111]. However,
ue to a lack of a general marker it has been difﬁcult to estimate the
requency of neuroendocrine differentiation in castration-resistant
atients. Cancer cells with a neuroendocrine pattern may  arise
hrough a trans-differentiation process from luminal cells. In vitro
vidence for a trans-differentiation process comes largely from
tudies performed with the androgen-responsive cell line LNCaP.
he morphology of these cells changes to a neuroendocrine-like
tate upon growth in androgen-depleted medium and is accom-
anied by a secretion of several neuroendocrine markers [112].
he underlying mechanisms of this androgen deprivation-induced
rans-differentiation include signalling via cAMP-activated PKA
esulting in phosphorylation of RHOA [113,114], human achaete-
cute homolog-1 (ASCL1) transcription factor [115], and receptor
rotein tyrosine phosphatase alpha (PTPRA) [116]. In addition,
ther factors and mechanisms such as IL6 through suppression
f RE-1 silencing transcription factor (REST) [117], inhibition
f NOTCH signalling leading to hypoxia [118], and cell-density-
nduced attenuation of CDK1/2 signalling [119] may  induce
euroendocrine trans-differentiation.
Normal and malignant neuroendocrine cells do not express AR,
nd are unlikely to be affected by AR-targeting therapies [120]. It
s therefore possible that while inactivation of AR decreases the
umber of luminal cells, malignant neuroendocrine cancer cells
ay  repopulate the vacant space in the prostatic tissue and thus
rive tumour recurrence. The pressure of AR-targeting therapy
ould select for a changed differentiation program in a common
alignant progenitor cell to a neuroendocrine rather than a luminal
henotype. Most neuroendocrine cells express CD44, which is also a
arker for the stem cell-containing, basal layer of the prostatic tis-
ue [121]. Furthermore SOX2, an embryonic stem cell regulator that
s repressed through AR signalling [122], is detected in basal cells
f benign prostate hyperplasia specimens and in neuroendocrine
umours of murine and human origin, while being absent in pri-
ary PCa tissues [123]. CBX2 and EZH2, members of the polycomb
roup, are involved in epigenetic regulation of neuroendocrine dif-
erentiation [124] and are upregulated in metastatic CRPCa samples
125]. The fusion TMPRSS2-ERG can be detected in neuroendocrine
ancers with a similar frequency to adenocarcinomas, showing that
oth cancer phenotypes have the same clonal origin [126]. When
aken together neuroendocrine differentiation may  be important
n response to AR targeting therapies and progression to castration
esistance, however due to a lack of adequate in vitro models and
iomarkers, it remains an under-explored area (Fig. 2a).
.2. Epithelial-to-mesenchymal transition
Epithelial-to-mesenchymal transition (EMT) as a mechanism of
astration resistance has been studied infrequently in the past and
linical evidence for an EMT  phenotype induced by AR-targeting
herapies is sparse. Despite this, there are several in vitro and ani-
al  studies which have explored EMT  as a resistance mechanism
ith interesting results. Recently, ADT-induced EMT  was  demon-trated in normal mouse prostate tissue and in the human LuCaP35
enograft model [127]. In addition, increased mRNA expression
f the mesenchymal markers Vimentin (VIM), ZEB1, Cadherin 11
CDH11) and Fibronectin 1 (FN1) was detected in human tissuer Biology 35 (2015) 133–144 137
specimens from patients that underwent ADT. However, another
study showed that DHT exposure led to EMT, higher migratory and
invasive potential and activation of the EMT-inducing transcription
factor Snail [128]. Interestingly, high AR expression can suppress
androgen-induced EMT. This conﬂicting data could be explained by
the observation that AR splice variants, that are induced through
AR-targeting therapies (see above), have a distinctive transcrip-
tional program compared to the full length receptor [62] and
might be responsible for the transition to a mesenchymal pheno-
type. Overexpression of constitutively active variants AR-V7 and
AR Q640X in LNCaP cells resulted in increased expression of mes-
enchymal markers [129]. Similarly androgen deprivation resulted
in an upregulation of AR-V7 and mesenchymal markers, both of
which can be reversed by the addition of DHT and reactivation of
the full length receptor [130]. In general, EMT  seems to be a rea-
sonable explanation for cancers with a mesenchymal phenotype
(Fig. 2b). However, to our knowledge there is as of yet no study
demonstrating that this mesenchymal phenotype is a consequence
of dedifferentiation of the epithelial phenotype or alternatively a
clonal expansion from an already existing mesenchymal pheno-
type.
5. Cancer stem cells
In the previous sections we have discussed several mechanisms
of therapy resistance, which may  be well-explained by a stochas-
tic model of cancer progression, i.e. that a random cell acquires a
survival beneﬁt in response to the treatment and gives rise to a
new, resistant tumour bulk. However, evidence increasingly sug-
gests that cancers are organised in a hierarchical manner, similar to
normal tissues, and that resistant tumours arise from cancer stem
cells that have adapted to the therapy environment.
5.1. Evidence for CSC in PCa
Since the ﬁrst report in 1994 of a role for stem cells in human
acute myeloid leukaemia subsequent reports have identiﬁed so-
called cancer stem cells (CSC) in a variety of tumours such as breast,
brain, colon, pancreas, lung, melanoma and glioblastoma [131]. CSC
represent a small population of cells inside a tumour which share
the characteristics of normal stem cells, i.e. self-renewal and the
ability to recapitulate the heterogeneous phenotype of the parental
cancers by differentiation [132]. However, the capacity to form a
parental-like tumour is not sufﬁcient to deﬁne a CSC; these tumours
must also be serially transplantable. In contrast to initial beliefs,
recent studies have suggested that around 25% of cancer cells may
have CSC properties [133].
Small CSC populations have also been detected in PCa [134].
Although the main hypothesis is that prostate cancer arises from
terminally differentiated luminal cells, there is growing evidence
that PCa arises from more undifferentiated cells with a basal phe-
notype [135–138]. In limiting dilution assays it was  demonstrated
that androgen-independent tumours arise from AR-negative cells
at a frequency of 1:105–106 AR-positive cells [139]. Interestingly,
AR-negative cells with very similar properties to stem cells have
been found in the PCa cell line LNCaP, which is meant to represent
luminal cancer cells [140]. In addition, the laboratory of Collins
and Maitland could isolate a population from primary PCa cells
with high clonogenic potential and the ability to differentiate into
luminal cells (AR+, ACPP+, ITGB2+), which were phenotypically
identical to normal stem cells (CD44+, ITGA2hi, PROM1+) [141].
PCa CSC have a unique miRNA expression proﬁle overlapping with
unfractionated advanced PCa and human embryonic SC [142].
Moreover, these cells express the cancer speciﬁc TMPRSS2:ETS
fusion genes [143]. In further support of this, CD44+ PCa xenograft
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iig. 2. Altered differentiation as therapy escape mechanisms. Histologic transfo
ic  intervention due to neuroendocrine (trans-)differentiation (a) and epithelial-to
reatment-naïve luminal tumour can give rise to a treatment-resistant luminal tum
ells possess enhanced tumour-initiating ability in vivo compared
o the CD44− population and could be successively serially trans-
lanted [144,145]. Lastly, one study demonstrated that tumours
ontaining luminal, basal and neuroendocrine cells could be
enerated in mice by using AR- and p63-negative cells expressing
he stem cell markers CD44, PROM1, nestin (NES) and KIT [146].
owever, although there is evidence that supports PCa originating
rom CSC, until now there is no study to our knowledge that has
hown that a single cell could form a tumour which both represents
 patient’s phenotype and which could be serially transplanted.
lso, due to the high heterogeneity of PCa, the possibility that CSC
xist in some but not all tumours should be considered.
.2. Role of CSC in therapy resistance
ADT, radio- and chemotherapy efﬁciently target the highly
roliferative and AR positive luminal cells representing the bulk
around 99%) of the tumour [138,141,147,148]. However, these
herapies fail to target the small population of quiescent and AR-
egative CSC, which are able to adapt to their new niche, resulting
n the regrowth of a therapy-resistant and more aggressive tumour
149]. Quiescence is generally a challenging problem to target due
o the fact that most therapeutics are designed to target highly pro-
iferative cells. In addition, quiescence is not the only reason for
rominent therapy resistance of CSC. High DNA repair activity is a
roperty of CSC which protects them from DNA damage-inducing
gents (e.g. Cisplatin) and radiotherapy [150]. PCa CSC sustained
ewer lethal double-strand breaks than more differentiated cells,
uggesting that CSC may  have increased DNA repair activity and
re therefore better equipped to deal with DNA damage [151]. Sev-
ral studies reported that CSC as well as normal stem cells have
n increased threshold for induction of mitochondrial apoptosis
ue to elevated expression of anti-apoptotic proteins (e.g. BCL2,
CL2L1 and MCL1) and members of the Inhibitor of Apoptosis fam-
ly (e.g. BIRC5) and are therefore more resistant to cytotoxic agentsns of the treatment-naïve luminal tumour may  occur in response to therapeu-
enchymal transition (EMT, b). A small population of cancer stem cells within the
a aberrant differentiation after/during therapeutic intervention (c).
[152–154]. We  have recently shown increased MCL1 mRNA expres-
sion in PCa CSC [155]. The BCL2 Homology Domain-3 mimetic
Obatoclax decreased the clonogenic efﬁciency of CD44+ prostate
cancer cells derived from a primary tumour supporting a role of the
BCL2 family in the tumour forming fraction of PCa. In addition to
the increased apoptotic threshold, CSC also have a high ability for
drug efﬂux through proteins such as ATP-binding cassette (ABC)
transporter family [156]. By using the Hoechst 33342 dye efﬂux
assay, a stem cell-enriched population was isolated from benign
and malignant prostate. This demonstrates that drug efﬂux trans-
porters are also highly active in prostate CSC and normal SC, and
consequently may  be able to efﬂux chemotherapeutic drugs across
the plasma membrane [157]. In conclusion, CSC have intrinsically
high resistance against various therapies, and they seem a reason-
able explanation for the high relapse of PCa after ADT and other
therapies (Fig. 2c). However more research is necessary in order
to prove the existence of these cells and to determine whether all
tumours harbour CSC.
6. Miscellaneous mechanisms
A number of signalling pathways have been found to be dereg-
ulated in PCa and to contribute to PCa progression. Receptor and
non-receptor kinases can circumvent the blocked AR pathway and
stimulate the proliferation and survival of the androgen-deprived
cells. As discussed above, this may  also lead to AR transactiva-
tion. A recent quantitative phosphoproteomic study with mCRPCa
samples revealed increased activation patterns for SRC, EGFR, RET
and ALK kinases compared to treatment-naïve specimens, although
with high inter-patient variability [158]. The IGF signalling path-
way may  also lead to PCa progression in patients undergoing ADT.
It was suggested that the hypogonadal state during ADT may  lead
to insulin resistance and/or obesity and increased IGF-1 expres-
sion, driving proliferation and survival of the malignant cells [159].
Insulin resistance, hyperglycemia and metabolic syndrome are
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Fig. 3. Summary of the reviewed therapy escape mechanisms in PCa. Prostate adenocarcinoma appears as disease of malignant cells with a luminal phenotype, which are
essentially dependent on androgenic signalling. Thus, the main therapy target is inactivation of AR. Various mechanisms confer acquired resistance to AR-targeting therapies.
These  include mechanisms modifying expression and transcriptional activity of AR (target modiﬁcation), activation of compensatory pathways to circumvent the inhibited
target  (bypass signalling), phenotypic changes of the epithelial cells (histologic transformation) and miscellaneous pro-survival and pro-proliferative mechanisms. However,
there  is increasing data that those mechanisms originate in cancer stem cells with a basal phenotype, which give rise to an aberrantly differentiated luminal phenotype under
the  pressure of the AR-targeting therapy.
k
l
t
o
p
[
r
r
s
o
p
t
l
r
i
t
s
t
gnown endocrine complications of ADT [160]. Another mechanism
eading to increased growth factor signalling is through inactiva-
ion of the phosphatase PTEN, which results in aberrant activation
f the PI3K-Akt pathway. Loss of PTEN occurs in about 50% of all PCa
atients [161] and its inactivation is sufﬁcient to initiate PCa in mice
162]. In that particular mouse model it was shown that castration-
esistant growth is an intrinsic property of Pten-null PCa cells, as a
esult of crosstalk between PI3K and AR [163]. Loss of PTEN expres-
ion is associated with poor survival and decreased time of patients
n abiraterone treatment [164], and it was proposed that PCa
atients with PTEN-deﬁciency might be better treated with PI3K-
han AR-targeting therapies [165]. The metal ion-binding metal-
othionein (MT) superfamily has also been implicated in treatment-
esistant prostate cancer. As there are unusually high levels of zinc
n the prostate compared to the rest of the body [166], it is possible
hat this tissue already has high basal MT  levels [167]. Carcinogene-
is and treatment may  further increase MT  expression levels by fac-
ors such as hypoxia [168], reactive oxygen species [169] and andro-
en deprivation [170]. The MT  protein is thought to play a role in anumber of pathways where it acts to increase proliferation [171],
reduce apoptosis [172] and scavenge free radicals [169], and thus
increased expression may  confer resistance to cells via these path-
ways [173]. However there are many MT  protein isoforms and thus
knowing exactly which ones are involved in resistance, and there-
fore which ones to target, currently proves troublesome. Another
side effect of ADT is increased inﬂammation through inﬁltration of
T-cells into the prostatic tissue [174]. Cytokines and chemokines
produced by the inﬁltrating immune cells, such as Interleukins-1,
-6, and -8 may drive proliferation and survival of prostate cancer
cells. In particular, serum IL6 levels are signiﬁcantly elevated in
CRPCa patients [175] and IL6 is known to upregulate expression of
MCL1, a member of the BCL2 family, thus promoting PCa cell sur-
vival [176]. High expression of MCL1 and PCa cell survival is also
a consequence of AR inactivation and subsequent cell cycle arrest
[155]. In conclusion, extrinsic and intrinsic mechanisms can lead
to increased growth factor production in the tumour environment
and increased signalling in the tumour cell resulting in stimulatory
effects supporting the cancer cell’s survival and proliferation.
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. Conclusions
The present review has summarised and classiﬁed various PCa
herapy escape mechanisms (Fig. 3). While some mechanisms occur
ore frequently, others are rare or their occurrence statistics are
ot available, mostly due to a lack of diagnostic detectability.
dditionally, due to the heterogeneity of the disease, multiple
echanisms of therapy resistance may  co-occur. It is important
o note that the same or similar concepts of escape mechanisms
s previously identiﬁed for ADT and CAB also confer resistance
o the second-generation drugs enzalutamide and abiraterone. As
 consequence, it remains difﬁcult to select the best treatment
ption in order to eliminate the risk of ab initio resistance. A
peciﬁc treatment sequence for CRPCa patients after chemother-
py failure is not available at the moment. The occurrence of
arious treatment resistances also gives a rationale for treating
atients as early as possible with combination therapies, where
deally two or more different molecular targets are hit at the
ame time. For instance, a recent clinical phase III study shows
romising results by treating patients with high-risk localised
Ca with a combination of ADT and the microtubule-targeting
gents docetaxel and estramustine compared to an ADT proto-
ol only [177]. Also, the identiﬁcation of CSC strongly argues for
he use of therapeutic combination regimes. Ideally, this would
nclude a therapy that targets the bulk of more differentiated, but
ighly proliferative cancer cells while the second aims to elimi-
ate the more undifferentiated, CSC-containing population of the
umour. This concept would recommend for PCa that treatment-
aïve tumours should be treated by the approved AR-targeting
nd/or radiation therapies in synergy with a protocol that targets
he CSC-containing, basal layer of the prostate. In conclusion, the
evelopment of novel AR-targeting therapies is well-justiﬁed in
rder to better target luminal, androgen-dependent PCa. However,
urther research should also aim to develop therapeutic options
o inactivate the CSC-containing, androgen-independent basal PCa
henotype.
onﬂict of interest statement
The authors declare that there are no conﬂicts of interest.
unding and acknowledgements
The authors would like to acknowledge the Austrian Science
und (FWF, Project P26799-B23 to FRS) and thank Prof. Dr. Nor-
an  Maitland (University of York) for providing comments to the
anuscript.
eferences
[1] McNeal JE. Normal and pathologic anatomy of prostate. Urology
1981;17:11–6.
[2] Isaacs JT. Prostate stem cells and benign prostatic hyperplasia. Prostate
2008;68:1025–34, http://dx.doi.org/10.1002/pros.20763.
[3] Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schröder FH,
van der Kwast TH. Do neuroendocrine cells in human prostate cancer
express androgen receptor? Histochemistry 1993;100:393–8.
[4] Lilja H, Abrahamsson PA. Three predominant proteins secreted by the
human prostate gland. Prostate 1988;12:29–38.
[5] Lang SH, Stark M,  Collins A, Paul AB, Stower MJ,  Maitland NJ. Experimental
prostate epithelial morphogenesis in response to stroma and
three-dimensional matrigel culture. Cell Growth Differ 2001;12:631–40.
[6] Rumpold H, Heinrich E, Untergasser G, Hermann M,  Pﬁster G, Plas E, et al.
Neuroendocrine differentiation of human prostatic primary epithelial cells
in vitro. Prostate 2002;53:101–8, http://dx.doi.org/10.1002/pros.10129.
[7]  Heidenreich A, Bastian PJ, Bellmunt J, Bolla M,  Joniau S, van der Kwast T,
et  al. EAU guidelines on prostate cancer. Part II: Treatment of advanced,
relapsing, and castration-resistant prostate cancer. Eur Urol
2014;65:467–79, http://dx.doi.org/10.1016/j.eururo.2013.11.002.r Biology 35 (2015) 133–144
[8] Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration,
of  estrogen and androgen injection on serum phosphatases in metastatic
carcinoma of the prostate. CA Cancer J Clin 1972;22:
232–40.
[9] Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased
survival with enzalutamide in prostate cancer after chemotherapy. N Engl J
Med  2012;367:1187–97, http://dx.doi.org/10.1056/NEJMoa1207506.
[10] Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone
acetate for treatment of metastatic castration-resistant prostate cancer:
Final overall survival analysis of the COU-AA-301 randomised, double-blind,
placebo-controlled phase 3 study. Lancet Oncol 2012;13:983–92,
http://dx.doi.org/10.1016/S1470-2045(12)70379-0.
[11] Beer TM,  Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al.
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J
Med  2014;371:424–33, http://dx.doi.org/10.1056/NEJMoa1405095.
[12] Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V,  et al. Development of a
second-generation antiandrogen for treatment of advanced prostate cancer.
Science 2009;324:787–90, http://dx.doi.org/10.1126/science.1168175.
[13] Lubahn DB, Brown TR, Simental JA, Higgs HN, Migeon CJ, Wilson EM,  et al.
Sequence of the intron/exon junctions of the coding region of the human
androgen receptor gene and identiﬁcation of a point mutation in a family
with complete androgen insensitivity. Proc Natl Acad Sci U S A
1989;86:9534–8.
[14] Jenster G, van der Korput HAGM, van Vroonhoven C, van der Kwast TH,
Trapman J, Brinkmann AO. Domains of the human androgen receptor
involved in steroid binding, transcriptional activation, and subcellular
localization. Mol  Endocrinol 1991;5:1396–404,
http://dx.doi.org/10.1210/mend-5-10-1396.
[15] Culig Z, Santer FR. Androgen receptor co-activators in the regulation of
cellular events in prostate cancer. World J Urol 2012;30:297–302,
http://dx.doi.org/10.1007/s00345-011-0797-6.
[16] Lovly CM, Shaw AT. Molecular pathways: Resistance to kinase inhibitors and
implications for therapeutic strategies. Clin Cancer Res 2014;20:2249–56,
http://dx.doi.org/10.1158/1078-0432.CCR-13-1610.
[17] Linja MJ,  Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T.
Ampliﬁcation and overexpression of androgen receptor gene in
hormone-refractory prostate cancer. Cancer Res 2001;61:
3550–5.
[18] Ford OH, Gregory CW,  Kim D, Smitherman AB, Mohler JL. Androgen receptor
gene ampliﬁcation and protein expression in recurrent prostate cancer. J
Urol 2003;170:1817–21,
http://dx.doi.org/10.1097/01.ju.0000091873.09677.f4.
[19] Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, et al. A
three-marker FISH panel detects more genetic aberrations of AR, PTEN and
TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in
primary prostate tumors. PLoS ONE 2013;8:e74671,
http://dx.doi.org/10.1371/journal.pone.0074671.
[20] Waltering KK, Helenius MA,  Sahu B, Manni V, Linja MJ,  Jänne OA, et al.
Increased expression of androgen receptor sensitizes prostate cancer cells to
low levels of androgens. Cancer Res 2009;69:8141–9,
http://dx.doi.org/10.1158/0008-5472.CAN-09-0919.
[21] Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM,  Waltering KK, et al.
Overexpression of androgen receptor enhances the binding of the receptor
to  the chromatin in prostate cancer. Oncogene 2012;31:2153–63,
http://dx.doi.org/10.1038/onc.2011.401.
[22] Merson S, Yang ZH, Brewer D, Olmos D, Eichholz A, McCarthy F, et al. Focal
ampliﬁcation of the androgen receptor gene in hormone-naive human
prostate cancer. Br J Cancer 2014;110:1655–62,
http://dx.doi.org/10.1038/bjc.2014.13.
[23] Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T.
Androgen receptor gene ampliﬁcation at primary progression predicts
response to combined androgen blockade as second line therapy for
advanced prostate cancer. J Urol 2000;164:1992–5.
[24] Shaffer DR, Leversha MA,  Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al.
Circulating tumor cell analysis in patients with progressive
castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023–9,
http://dx.doi.org/10.1158/1078-0432.CCR-06-2701.
[25]  Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, et al. Androgen
receptor is the key transcriptional mediator of the tumor suppressor SPOP
in prostate cancer. Cancer Res 2014;74:5631–43,
http://dx.doi.org/10.1158/0008-5472.CAN-14-0476.
[26]  An J, Wang C, Deng Y, Yu L, Huang H.  Destruction of full-length androgen
receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
Cell Rep 2014;6:657–69, http://dx.doi.org/10.1016/j.celrep.2014.01.013.
[27]  Barbieri CE, Baca SC, Lawrence MS,  Demichelis F, Blattner M,  Theurillat J-P,
et  al. Exome sequencing identiﬁes recurrent SPOP, FOXA1 and MED12
mutations in prostate cancer. Nat Genet 2012;44:685–9,
http://dx.doi.org/10.1038/ng.2279.[28] Grasso CS, Wu  Y-M, Robinson DR, Cao X, Dhanasekaran SM,  Khan AP, et al.
The  mutational landscape of lethal castration-resistant prostate cancer.
Nature 2012;487:239–43, http://dx.doi.org/10.1038/nature11125.
[29] Qi J, Tripathi M,  Mishra R, Sahgal N, Fazli L, Fazil L, et al. The E3 ubiquitin
ligase Siah2 contributes to castration-resistant prostate cancer by regulation
 CanceF.R. Santer et al. / Seminars in
of androgen receptor transcriptional activity. Cancer Cell 2013;23:332–46,
http://dx.doi.org/10.1016/j.ccr.2013.02.016.
[30] Köhler A, Demir U, Kickstein E, Krauss S, Aigner J, Aranda-Orgillés B, et al. A
hormone-dependent feedback-loop controls androgen receptor levels by
limiting MID1, a novel translation enhancer and promoter of oncogenic
signaling. Mol  Cancer 2014;13:146,
http://dx.doi.org/10.1186/1476-4598-13-146.
[31] Quarmby VE, Yarbrough WG,  Lubahn DB, French FS, Wilson EM.  Autologous
down-regulation of androgen receptor messenger ribonucleic acid. Mol
Endocrinol 1990;4:22–8, http://dx.doi.org/10.1210/mend-4-1-22.
[32] Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor
gene expression in prostate cancer is directly suppressed by the androgen
receptor through recruitment of lysine-speciﬁc demethylase 1. Cancer Cell
2011;20:457–71, http://dx.doi.org/10.1016/j.ccr.2011.09.001.
[33] McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in
human prostate cancer: Structural analysis of mutant androgen receptors
from LNCaP and CWR22 tumors. Cancer Res 2000;60:2317–22.
[34] Azad AA, Volik SV, Wyatt AW,  Haegert A, Le Bihan S, Bell RH, et al. Androgen
receptor gene aberrations in circulating cell-free DNA: Biomarkers of
therapeutic resistance in castration-resistant prostate cancer. Clin Cancer
Res 2015, http://dx.doi.org/10.1158/1078-0432.CCR-14-2666.
[35] Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically
relevant androgen receptor mutation confers resistance to
second-generation antiandrogens enzalutamide and ARN-509. Cancer
Discov 2013;3:1020–9, http://dx.doi.org/10.1158/2159-8290.CD-13-0226.
[36] Korpal M,  Korn JM,  Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L
mutation in androgen receptor confers genetic and phenotypic resistance to
MDV3100 (enzalutamide). Cancer Discov 2013;3:1030–43,
http://dx.doi.org/10.1158/2159-8290.CD-13-0142.
[37] Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, et al.
Abiraterone treatment in castration-resistant prostate cancer selects for
progesterone responsive mutant androgen receptors. Clin Cancer Res
2015;21:1273–80, http://dx.doi.org/10.1158/1078-0432.CCR-14-1220.
[38] Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, et al.
Antiandrogen bicalutamide promotes tumor growth in a novel
androgen-dependent prostate cancer xenograft model derived from a
bicalutamide-treated patient. Cancer Res 2005;65:9611–6,
http://dx.doi.org/10.1158/0008-5472.CAN-05-0817.
[39] Culig Z, Hobisch A, Cronauer MV,  Cato AC, Hittmair A, Radmayr C, et al.
Mutant androgen receptor detected in an advanced-stage prostatic
carcinoma is activated by adrenal androgens and progesterone. Mol
Endocrinol 1993;7:1541–50, http://dx.doi.org/10.1210/mend.7.12.8145761.
[40] Tan J, Sharief Y, Hamil KG, Gregory CW,  Zang D-Y, Sar M,  et al.
Dehydroepiandrosterone activates mutant androgen receptors expressed in
the androgen-dependent human prostate cancer xenograft CWR22 and
LNCaP cells. Mol  Endocrinol 1997;11:450–9,
http://dx.doi.org/10.1210/mend.11.4.9906.
[41] Taplin ME,  Bubley GJ, Ko YJ, Small EJ, Upton M,  Rajeshkumar B, et al.
Selection for androgen receptor mutations in prostate cancers treated with
androgen antagonist. Cancer Res 1999;59:2511–5.
[42] Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM,  et al.
Glucocorticoids can promote androgen-independent growth of prostate
cancer cells through a mutated androgen receptor. Nat Med  2000;6:703–6,
http://dx.doi.org/10.1038/76287.
[43] Culig Z, Stober J, Gast A, Peterziel H, Hobisch A, Radmayr C, et al. Activation
of  two mutant androgen receptors from human prostatic carcinoma by
adrenal androgens and metabolic derivatives of testosterone. Cancer Detect
Prev 1996;20:68–75.
[44] Rodriguez-Vida A, Bianchini D, Van Hemelrijck M,  Hughes S, Malik Z, Powles
T,  et al. Is there an antiandrogen withdrawal syndrome with enzalutamide?
BJU Int 2015;115:373–80, http://dx.doi.org/10.1111/bju.12826.
[45] Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J Urol
1995;153:1070–2 (discussion 1072–1073).
[46] Scher HI, Kelly WK.  Flutamide withdrawal syndrome: Its impact on clinical
trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566–72.
[47] Ni L, Llewellyn R, Kesler CT, Kelley JB, Spencer A, Snow CJ, et al. Androgen
induces a switch from cytoplasmic retention to nuclear import of the
androgen receptor. Mol  Cell Biol 2013;33:4766–78,
http://dx.doi.org/10.1128/MCB.00647-13.
[48] Duff J, McEwan IJ. Mutation of histidine 874 in the androgen receptor
ligand-binding domain leads to promiscuous ligand activation and altered
p160 coactivator interactions. Mol  Endocrinol 2005;19:2943–54,
http://dx.doi.org/10.1210/me.2005-0231.
[49] Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM,  Kung H-J, Mudryj M.
Evidence for calpain-mediated androgen receptor cleavage as a mechanism
for androgen independence. Cancer Res 2007;67:9001–5,
http://dx.doi.org/10.1158/0008-5472.CAN-07-1072.
[50] Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR
intragenic deletions linked to androgen receptor splice variant expression
and activity in models of prostate cancer progression. Oncogene
2012;31:4759–67, http://dx.doi.org/10.1038/onc.2011.637.
[51] Nyquist MD,  Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KAT, et al.
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling ofr Biology 35 (2015) 133–144 141
androgen receptor in prostate cancer. Proc Natl Acad Sci U S A
2013;110:17492–7, http://dx.doi.org/10.1073/pnas.1308587110.
[52] Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X. Mechanisms of the
androgen receptor splicing in prostate cancer cells. Oncogene
2014;33:3140–50, http://dx.doi.org/10.1038/onc.2013.284.
[53] Lu J, Van der Steen T, Tindall DJ. Are androgen receptor variants a substitute
for the full-length receptor? Nat Rev Urol 2015;12:137–44,
http://dx.doi.org/10.1038/nrurol.2015.13.
[54] Streicher W,  Zengerling F, Laschak M,  Weidemann W,  Höpfner M,  Schrader
AJ,  et al. AR-Q640X, a model to study the effects of constitutively active
C-terminally truncated AR variants in prostate cancer cells. World J Urol
2012;30:333–9, http://dx.doi.org/10.1007/s00345-012-0842-0.
[55] Chan SC, Li Y, Dehm SM.  Androgen receptor splice variants activate
androgen receptor target genes and support aberrant prostate cancer cell
growth independent of canonical androgen receptor nuclear localization
signal. J Biol Chem 2012;287:19736–49,
http://dx.doi.org/10.1074/jbc.M112.352930.
[56] Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM,
et al. Resistance to CYP17A1 inhibition with abiraterone in
castration-resistant prostate cancer: Induction of steroidogenesis and
androgen receptor splice variants. Clin Cancer Res 2011;17:5913–25,
http://dx.doi.org/10.1158/1078-0432.CCR-11-0728.
[57] Li Y, Chan SC, Brand LJ, Hwang TH,  Silverstein KAT, Dehm SM.  Androgen
receptor splice variants mediate enzalutamide resistance in
castration-resistant prostate cancer cell lines. Cancer Res 2013;73:483–9,
http://dx.doi.org/10.1158/0008-5472.CAN-12-3630.
[58] Hu R, Dunn TA, Wei  S, Isharwal S, Veltri RW,  Humphreys E, et al.
Ligand-independent androgen receptor variants derived from splicing of
cryptic exons signify hormone-refractory prostate cancer. Cancer Res
2009;69:16–22, http://dx.doi.org/10.1158/0008-5472.CAN-08-2764.
[59] Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, et al. Constitutively active AR-V7
plays an essential role in the development and progression of
castration-resistant prostate cancer. Sci Rep 2015;5:7654,
http://dx.doi.org/10.1038/srep07654.
[60] Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, et al.
Rapid induction of androgen receptor splice variants by androgen
deprivation in prostate cancer. Clin Cancer Res 2014;20:1590–600,
http://dx.doi.org/10.1158/1078-0432.CCR-13-1863.
[61] Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M,  Roeser JC, et al. AR-V7
and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J
Med  2014;371:1028–38, http://dx.doi.org/10.1056/NEJMoa1315815.
[62] Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M,  Tannahill C, et al.
Distinct transcriptional programs mediated by the ligand-dependent
full-length androgen receptor and its splice variants in castration-resistant
prostate cancer. Cancer Res 2012;72:3457–62,
http://dx.doi.org/10.1158/0008-5472.CAN-11-3892.
[63] Hobisch A, Eder IE, Putz T, Horninger W,  Bartsch G, Klocker H,  et al.
Interleukin-6 regulates prostate-speciﬁc protein expression in prostate
carcinoma cells by activation of the androgen receptor. Cancer Res
1998;58:4640–5.
[64] Yang L, Wang L, Lin H-K, Kan P-Y, Xie S, Tsai M-Y, et al. Interleukin-6
differentially regulates androgen receptor transactivation via PI3K-Akt,
STAT3, and MAPK, three distinct signal pathways in prostate cancer cells.
Biochem Biophys Res Commun 2003;305:462–9.
[65] Ueda T, Bruchovsky N, Sadar MD.  Activation of the androgen receptor
N-terminal domain by interleukin-6 via MAPK and STAT3 signal
transduction pathways. J Biol Chem 2002;277:7076–85,
http://dx.doi.org/10.1074/jbc.M108255200.
[66] Ueda T, Mawji NR, Bruchovsky N, Sadar MD.  Ligand-independent activation
of  the androgen receptor by interleukin-6 and the role of steroid receptor
coactivator-1 in prostate cancer cells. J Biol Chem 2002;277:38087–94,
http://dx.doi.org/10.1074/jbc.M203313200.
[67] Rocha J, Zouanat FZ, Zoubeidi A, Hamel L, Benidir T, Scarlata E, et al. The Fer
tyrosine kinase acts as a downstream interleukin-6 effector of androgen
receptor activation in prostate cancer. Mol  Cell Endocrinol 2013;381:140–9,
http://dx.doi.org/10.1016/j.mce.2013.07.017.
[68] Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, et al.
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo
through activation of the androgen receptor. Endocr Relat Cancer
2009;16:155–69, http://dx.doi.org/10.1677/ERC-08-0174.
[69] Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, et al. Regulation of androgen
receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309–19,
http://dx.doi.org/10.1016/j.ccr.2006.08.021.
[70] Summy  JM,  Gallick GE. Src family kinases in tumor progression and
metastasis. Cancer Metastasis Rev 2003;22:337–58.
[71] Desai SJ, Ma  A-H, Tepper CG, Chen H-W, Kung H-J. Inappropriate activation
of  the androgen receptor by nonsteroids: Involvement of the Src kinase
pathway and its therapeutic implications. Cancer Res 2006;66:10449–59,
http://dx.doi.org/10.1158/0008-5472.CAN-06-2582.
[72] Culig Z, Hobisch A, Cronauer MV,  Radmayr C, Trapman J, Hittmair A, et al.
Androgen receptor activation in prostatic tumor cell lines by insulin-like
growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Cancer Res 1994;54:5474–8.
1  Cance42 F.R. Santer et al. / Seminars in
[73] Heemers HV, Regan KM,  Schmidt LJ, Anderson SK, Ballman KV, Tindall DJ.
Androgen modulation of coregulator expression in prostate cancer cells.
Mol  Endocrinol 2009;23:572–83, http://dx.doi.org/10.1210/me.2008-0363.
[74] Heemers HV, Sebo TJ, Debes JD, Regan KM,  Raclaw KA, Murphy LM,  et al.
Androgen deprivation increases p300 expression in prostate cancer cells.
Cancer Res 2007;67:3422–30,
http://dx.doi.org/10.1158/0008-5472.CAN-06-2836.
[75] Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 Mediates
androgen-independent transactivation of the androgen receptor by
interleukin 6. Cancer Res 2002;62:5632–6.
[76] Gong J, Zhu J, Goodman OB, Pestell RG, Schlegel PN, Nanus DM,  et al.
Activation of p300 histone acetyltransferase activity and acetylation of the
androgen receptor by bombesin in prostate cancer cells. Oncogene
2006;25:2011–21, http://dx.doi.org/10.1038/sj.onc.1209231.
[77] Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M,  Pycha A, et al. The
androgen receptor co-activator CBP is up-regulated following androgen
withdrawal and is highly expressed in advanced prostate cancer. J Pathol
2004;204:159–66, http://dx.doi.org/10.1002/path.1609.
[78] Merkle D, Hoffmann R. Roles of cAMP and cAMP-dependent protein kinase
in  the progression of prostate cancer: Cross-talk with the androgen receptor.
Cell Signal 2011;23:507–15, http://dx.doi.org/10.1016/j.cellsig.2010.08.017.
[79]  Kim J, Jia L, Stallcup MR,  Coetzee GA. The role of protein kinase A pathway
and cAMP responsive element-binding protein in androgen
receptor-mediated transcription at the prostate-speciﬁc antigen locus. J Mol
Endocrinol 2005;34:107–18, http://dx.doi.org/10.1677/jme.1.01701.
[80]  Choi H-K, Yoo J-Y, Jeong M-H, Park S-Y, Shin D-M, Jang S-W, et al. Protein
kinase A phosphorylates NCoR to enhance its nuclear translocation and
repressive function in human prostate cancer cells. J Cell Physiol
2013;228:1159–65, http://dx.doi.org/10.1002/jcp.24269.
[81] Laschak M,  Bechtel M, Spindler K-D, Hessenauer A. Inability of NCoR/SMRT
to  repress androgen receptor transcriptional activity in prostate cancer cell
lines. Int J Mol  Med 2011;28:645–51,
http://dx.doi.org/10.3892/ijmm.2011.735.
[82] Godoy AS, Sotomayor PC, Villagran M, Yacoub R, Montecinos VP, McNerney
EM,  et al. Altered corepressor SMRT expression and recruitment to target
genes as a mechanism that change the response to androgens in prostate
cancer progression. Biochem Biophys Res Commun 2012;423:564–70,
http://dx.doi.org/10.1016/j.bbrc.2012.06.005.
[83] Mäki HE, Saramäki OR, Shatkina L, Martikainen PM,  Tammela TLJ, van
Weerden WM,  et al. Overexpression and gene ampliﬁcation of BAG-1L in
hormone-refractory prostate cancer. J Pathol 2007;212:395–401,
http://dx.doi.org/10.1002/path.2186.
[84] Jehle K, Cato L, Neeb A, Muhle-Goll C, Jung N, Smith EW,  et al. Coregulator
control of androgen receptor action by a novel nuclear receptor-binding
motif. J Biol Chem 2014;289:8839–51,
http://dx.doi.org/10.1074/jbc.M113.534859.
[85] Khanna M,  Qin KN, Wang RW,  Cheng KC. Substrate speciﬁcity, gene
structure, and tissue-speciﬁc distribution of multiple human 3
alpha-hydroxysteroid dehydrogenases. J Biol Chem 1995;270:20162–8.
[86] Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA,  Penning TM,  et al.
Increased expression of genes converting adrenal androgens to testosterone
in  androgen-independent prostate cancer. Cancer Res 2006;66:2815–25,
http://dx.doi.org/10.1158/0008-5472.CAN-05-4000.
[87] Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al.
Androgen levels increase by intratumoral de novo steroidogenesis during
progression of castration-resistant prostate cancer. Cancer Res
2008;68:6407–15, http://dx.doi.org/10.1158/0008-5472.CAN-07-5997.
[88] Mostaghel EA, Page ST, Lin DW,  Fazli L, Coleman IM,  True LD, et al.
Intraprostatic androgens and androgen-regulated gene expression persist
after testosterone suppression: Therapeutic implications for
castration-resistant prostate cancer. Cancer Res 2007;67:5033–41,
http://dx.doi.org/10.1158/0008-5472.CAN-06-3332.
[89] Liu C, Lou W,  Zhu Y, Yang JC, Nadiminty N, Gaikwad NW,  et al. Intracrine
androgens and AKR1C3 activation confer resistance to enzalutamide in
prostate cancer. Cancer Res 2015;75:1413–22,
http://dx.doi.org/10.1158/0008-5472.CAN-14-3080.
[90] Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM,  Mehra R, Sun XW,  et al.
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate
cancer. Science 2005;310:644–8,
http://dx.doi.org/10.1126/science.1117679.
[91] Powell K, Semaan L, Conley-LaComb MK,  Asangani I, Wu Y-M, Ginsburg KB,
et  al. ERG/AKR1C3/AR constitutes a feed-forward loop for AR signaling in
prostate cancer cells. Clin Cancer Res 2015,
http://dx.doi.org/10.1158/1078-0432.CCR-14-2352.
[92] Danila DC, Anand A, Sung CC, Heller G, Leversha MA,  Cao L, et al.
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of
sensitivity in castration-resistant prostate cancer patients treated with
abiraterone acetate. Eur Urol 2011;60:897–904,
http://dx.doi.org/10.1016/j.eururo.2011.07.011.
[93] Yin YD, Fu M, Brooke DG, Heinrich DM,  Denny WA,  Jamieson SMF. The
activity of SN33638, an inhibitor of AKR1C3, on testosterone and
17-estradiol production and function in castration-resistant prostater Biology 35 (2015) 133–144
cancer and ER-positive breast cancer. Front Oncol 2014;4:159,
http://dx.doi.org/10.3389/fonc.2014.00159.
[94] Chang K-H, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, et al. A gain-of-function
mutation in DHT synthesis in castration-resistant prostate cancer. Cell
2013;154:1074–84, http://dx.doi.org/10.1016/j.cell.2013.07.029.
[95]  Uemura M,  Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, et al.
Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in
hormone-refractory prostate cancer. Cancer Sci 2008;99:81–6,
http://dx.doi.org/10.1111/j.1349-7006.2007.00656.x.
[96] Titus MA,  Gregory CW,  Ford OH, Schell MJ,  Maygarden SJ, Mohler JL. Steroid
5-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res
2005;11:4365–71, http://dx.doi.org/10.1158/1078-0432.CCR-04-0738.
[97] Uemura M,  Honma S, Chung S, Takata R, Furihata M,  Nishimura K, et al.
5DH-DOC (5-dihydro-deoxycorticosterone) activates androgen receptor
in  castration-resistant prostate cancer. Cancer Sci 2010;101:1897–904,
http://dx.doi.org/10.1111/j.1349-7006.2010.01620.x.
[98] Chang K-H, Li R, Papari-Zareei M,  Watumull L, Zhao YD, Auchus RJ, et al.
Dihydrotestosterone synthesis bypasses testosterone to drive
castration-resistant prostate cancer. Proc Natl Acad Sci U S A
2011;108:13728–33, http://dx.doi.org/10.1073/pnas.1107898108.
[99]  Fukami M,  Homma K, Hasegawa T, Ogata T. Backdoor pathway for
dihydrotestosterone biosynthesis: Implications for normal and abnormal
human sex development. Dev Dyn 2013;242:320–9,
http://dx.doi.org/10.1002/dvdy.23892.
[100] Mostaghel EA. Beyond T and DHT – Novel steroid derivatives capable of wild
type androgen receptor activation. Int J Biol Sci 2014;10:602–13,
http://dx.doi.org/10.7150/ijbs.8844.
[101] Jernberg E, Thysell E, Bovinder Ylitalo E, Rudolfsson S, Crnalic S, Widmark A,
et  al. Characterization of prostate cancer bone metastases according to
expression levels of steroidogenic enzymes and androgen receptor splice
variants. PLoS ONE 2013;8:e77407,
http://dx.doi.org/10.1371/journal.pone.0077407.
[102] Hoﬂand J, van Weerden WM,  Dits NFJ, Steenbergen J, van Leenders GJLH,
Jenster G, et al. Evidence of limited contributions for intratumoral
steroidogenesis in prostate cancer. Cancer Res 2010;70:1256–64,
http://dx.doi.org/10.1158/0008-5472.CAN-09-2092.
[103] Auchus RJ, Yu MK,  Nguyen S, Mundle SD. Use of prednisone with abiraterone
acetate in metastatic castration-resistant prostate cancer. Oncologist
2014;19:1231–40, http://dx.doi.org/10.1634/theoncologist.2014-0167.
[104] Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD,  et al.
Glucocorticoid receptor confers resistance to antiandrogens by bypassing
androgen receptor blockade. Cell 2013;155:1309–22,
http://dx.doi.org/10.1016/j.cell.2013.11.012.
[105] Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, et al.
Differential targeting of androgen and glucocorticoid receptors induces ER
stress and apoptosis in prostate cancer cells. Cell Cycle 2012;11:395–406,
http://dx.doi.org/10.4161/cc.11.2.18945.
[106] Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, et al. The expression of
glucocorticoid receptor is negatively regulated by active androgen receptor
signaling in prostate tumors. Int J Cancer 2015;136:E27–38,
http://dx.doi.org/10.1002/ijc.29147.
[107] Pan D, Kocherginsky M,  Conzen SD. Activation of the glucocorticoid receptor
is  associated with poor prognosis in estrogen receptor-negative breast
cancer. Cancer Res 2011;71:6360–70,
http://dx.doi.org/10.1158/0008-5472.CAN-11-0362.
[108] Epstein JI, Amin MB,  Beltran H, Lotan TL, Mosquera J-M, Reuter VE, et al.
Proposed morphologic classiﬁcation of prostate cancer with neuroendocrine
differentiation. Am J Surg Pathol 2014;38:756–67,
http://dx.doi.org/10.1097/PAS.0000000000000208.
[109] Puccetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquaniti S, et al.
Skewing towards neuroendocrine phenotype in high grade or high stage
androgen-responsive primary prostate cancer. Eur Urol 2005;48:215–21,
http://dx.doi.org/10.1016/j.eururo.2005.03.018 (discussion 221–223).
[110] Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine
differentiation in hormone refractory prostate cancer following androgen
deprivation therapy. Eur Urol 2004;45:586–92,
http://dx.doi.org/10.1016/j.eururo.2003.11.032.
[111] Lipianskaya J, Cohen A, Chen CJ, Hsia E, Squires J, Li Z, et al.
Androgen-deprivation therapy-induced aggressive prostate cancer with
neuroendocrine differentiation. Asian J Androl 2014;16:541–4,
http://dx.doi.org/10.4103/1008-682X.123669.
[112] Yuan T-C, Veeramani S, Lin F-F, Kondrikou D, Zelivianski S, Igawa T, et al.
Androgen deprivation induces human prostate epithelial neuroendocrine
differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer
2006;13:151–67, http://dx.doi.org/10.1677/erc.1.01043.
[113] Kvissel A-K, Ramberg H, Eide T, Svindland A, Skålhegg BS, Taskén KA.
Androgen dependent regulation of protein kinase A subunits in prostate
cancer cells. Cell Signal 2007;19:401–9,
http://dx.doi.org/10.1016/j.cellsig.2006.07.011.
[114] Jones SE, Palmer TM.  Protein kinase A-mediated phosphorylation of RhoA on
serine 188 triggers the rapid induction of a neuroendocrine-like phenotype
 Cance
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[F.R. Santer et al. / Seminars in
in prostate cancer epithelial cells. Cell Signal 2012;24:1504–14,
http://dx.doi.org/10.1016/j.cellsig.2012.03.018.
115] Rapa I, Volante M,  Migliore C, Farsetti A, Berruti A, Vittorio Scagliotti G, et al.
Human ASH-1 promotes neuroendocrine differentiation in androgen
deprivation conditions and interferes with androgen responsiveness in
prostate cancer cells. Prostate 2013;73:1241–9,
http://dx.doi.org/10.1002/pros.22679.
116] Zhang X-Q, Kondrikov D, Yuan T-C, Lin F-F, Hansen J, Lin M-F. Receptor
protein tyrosine phosphatase alpha signaling is involved in androgen
depletion-induced neuroendocrine differentiation of androgen-sensitive
LNCaP human prostate cancer cells. Oncogene 2003;22:6704–16,
http://dx.doi.org/10.1038/sj.onc.1206764.
117] Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W,  Gao AC. Interleukin-6 induces
neuroendocrine differentiation (NED) through suppression of RE-1 silencing
transcription factor (REST). Prostate 2014;74:1086–94,
http://dx.doi.org/10.1002/pros.22819.
118] Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, et al. Notch
signaling modulates hypoxia-induced neuroendocrine differentiation of
human prostate cancer cells. Mol  Cancer Res 2012;10:230–8,
http://dx.doi.org/10.1158/1541-7786.MCR-11-0296.
119] Pernicová Z, Slabáková E, Fedr R, Sˇimecˇková Sˇ, Jarosˇ J, Suchánková T, et al.
The  role of high cell density in the promotion of neuroendocrine
transdifferentiation of prostate cancer cells. Mol  Cancer 2014;13:113,
http://dx.doi.org/10.1186/1476-4598-13-113.
120] Lin D, Wyatt AW,  Xue H, Wang Y, Dong X, Haegert A, et al. High ﬁdelity
patient-derived xenografts for accelerating prostate cancer discovery and
drug development. Cancer Res 2014;74:1272–83,
http://dx.doi.org/10.1158/0008-5472.CAN-13-2921-T.
121] Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, et al.
Selective expression of CD44, a putative prostate cancer stem cell marker, in
neuroendocrine tumor cells of human prostate cancer. Prostate
2009;69:787–98, http://dx.doi.org/10.1002/pros.20928.
122] Kregel S, Kiriluk KJ, Rosen AM,  Cai Y, Reyes EE, Otto KB, et al. Sox2 is an
androgen receptor-repressed gene that promotes castration-resistant
prostate cancer. PLoS ONE 2013;8:e53701,
http://dx.doi.org/10.1371/journal.pone.0053701.
123] Yu X, Cates JM,  Morrissey C, You C, Grabowska MM,  Zhang J, et al. SOX2
expression in the developing, adult, as well as, diseased prostate. Prostate
Cancer Prostatic Dis 2014;17:301–9,
http://dx.doi.org/10.1038/pcan.2014.29.
124] Clermont P-L, Lin D, Crea F, Wu R, Xue H, Wang Y, et al. Polycomb-mediated
silencing in neuroendocrine prostate cancer. Clin Epigenetics 2015;7:40,
http://dx.doi.org/10.1186/s13148-015-0074-4.
125] Varambally S, Dhanasekaran SM,  Zhou M,  Barrette TR, Kumar-Sinha C, Sanda
MG, et al. The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature 2002;419:624–9,
http://dx.doi.org/10.1038/nature01075.
126] Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al.
Molecular characterization of neuroendocrine prostate cancer and
identiﬁcation of new drug targets. Cancer Discov 2011;1:487–95,
http://dx.doi.org/10.1158/2159-8290.CD-11-0130.
127] Sun Y, Wang B-E, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen
deprivation causes epithelial–mesenchymal transition in the prostate:
Implications for androgen-deprivation therapy. Cancer Res
2012;72:527–36, http://dx.doi.org/10.1158/0008-5472.CAN-11-3004.
128] Zhu M-L, Kyprianou N. Role of androgens and the androgen receptor in
epithelial-mesenchymal transition and invasion of prostate cancer cells.
FASEB J 2010;24:769–77, http://dx.doi.org/10.1096/fj.09-136994.
129] Cottard F, Asmane I, Erdmann E, Bergerat J-P, Kurtz J-E, Céraline J.
Constitutively active androgen receptor variants upregulate expression of
mesenchymal markers in prostate cancer cells. PLoS ONE 2013;8:e63466,
http://dx.doi.org/10.1371/journal.pone.0063466.
130] Kong D, Sethi S, Li Y, Chen W,  Sakr WA,  Heath E, et al. Androgen receptor
splice variants contribute to prostate cancer aggressiveness through
induction of EMT  and expression of stem cell marker genes. Prostate
2015;75:161–74, http://dx.doi.org/10.1002/pros.22901.
131] Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating
evidence and unresolved questions. Nat Rev Cancer 2008;8:755–68,
http://dx.doi.org/10.1038/nrc2499.
132] Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: Cancer stem cells in
metastasis. Cell Res 2007;17:3–14, http://dx.doi.org/10.1038/sj.cr.7310118.
133] Kelly PN, Dakic A, Adams JM,  Nutt SL, Strasser A. Tumor growth need not be
driven by rare cancer stem cells. Science 2007;317:337,
http://dx.doi.org/10.1126/science.1142596.
134] Van Leenders GJ, Schalken JA. Stem cell differentiation within the human
prostate epithelium: Implications for prostate carcinogenesis. BJU Int
2001;88(Suppl 2):35–42 (discussion 49–50).135] Nagle RB, Ahmann FR, McDaniel KM,  Paquin ML,  Clark VA, Celniker A.
Cytokeratin characterization of human prostatic carcinoma and its derived
cell lines. Cancer Res 1987;47:281–6.
136] De Marzo AM,  Meeker AK, Epstein JI, Coffey DS. Prostate stem cell
compartments: Expression of the cell cycle inhibitor p27Kip1 in normal,r Biology 35 (2015) 133–144 143
hyperplastic, and neoplastic cells. Am J Pathol 1998;153:911–9,
http://dx.doi.org/10.1016/S0002-9440(10)65632-5.
[137] Stoyanova T, Cooper AR, Drake JM,  Liu X, Armstrong AJ, Pienta KJ, et al.
Prostate cancer originating in basal cells progresses to adenocarcinoma
propagated by luminal-like cells. Proc Natl Acad Sci U S A
2013;110:20111–6, http://dx.doi.org/10.1073/pnas.1320565110.
[138] Grisanzio C, Signoretti S. p63 in prostate biology and pathology. J Cell
Biochem 2008;103:1354–68, http://dx.doi.org/10.1002/jcb.21555.
[139] Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, et al. Evidence
for  clonal outgrowth of androgen-independent prostate cancer cells from
androgen-dependent tumors through a two-step process. Cancer Res
1999;59:5030–6.
[140] Qin J, Liu X, Lafﬁn B, Chen X, Choy G, Jeter CR, et al. The PSA(-/lo) prostate
cancer cell population harbors self-renewing long-term tumor-propagating
cells that resist castration. Cell Stem Cell 2012;10:556–69,
http://dx.doi.org/10.1016/j.stem.2012.03.009.
[141] Collins AT, Berry PA, Hyde C, Stower MJ,  Maitland NJ. Prospective
identiﬁcation of tumorigenic prostate cancer stem cells. Cancer Res
2005;65:10946–51, http://dx.doi.org/10.1158/0008-5472.CAN-05-2018.
[142] Rane JK, Scaravilli M,  Ylipaa A, Pellacani D, Mann VM,  Simms MS,  et al.
MicroRNA expression proﬁle of primary prostate cancer stem cells as a
source of biomarkers and therapeutic targets. Eur Urol 2015;67:7–10,
http://dx.doi.org/10.1016/j.eururo.2014.09.005.
[143] Polson ES, Lewis JL, Celik H, Mann VM,  Stower MJ,  Simms MS,  et al.
Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat
Commun 2013;4:1623, http://dx.doi.org/10.1038/ncomms2627.
[144] Kroon P, Berry PA, Stower MJ,  Rodrigues G, Mann VM,  Simms  M,  et al.
JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of
prostate cancer stem-like cells. Cancer Res 2013;73:5288–98,
http://dx.doi.org/10.1158/0008-5472.CAN-13-0874.
[145] Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al.
Highly puriﬁed CD44+ prostate cancer cells from xenograft human tumors
are  enriched in tumorigenic and metastatic progenitor cells. Oncogene
2006;25:1696–708, http://dx.doi.org/10.1038/sj.onc.1209327.
[146] Gu G, Yuan J, Wills M,  Kasper S. Prostate cancer cells with stem cell
characteristics reconstitute the original human tumor in vivo. Cancer Res
2007;67:4807–15, http://dx.doi.org/10.1158/0008-5472.CAN-06-4608.
[147] Rane JK, Pellacani D, Maitland NJ. Advanced prostate cancer – A case for
adjuvant differentiation therapy. Nat Rev Urol 2012;9:595–602,
http://dx.doi.org/10.1038/nrurol.2012.157.
[148] Oldridge EE, Pellacani D, Collins AT, Maitland NJ. Prostate cancer stem cells:
Are they androgen-responsive? Mol  Cell Endocrinol 2012;360:14–24,
http://dx.doi.org/10.1016/j.mce.2011.07.008.
[149] Lang SH, Anderson E, Fordham R, Collins AT. Modeling the prostate stem cell
niche: An evaluation of stem cell survival and expansion in vitro. Stem Cells
Dev  2010;19:537–46, http://dx.doi.org/10.1089/scd.2009.0291.
[150] Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem
cells promote radioresistance by preferential activation of the DNA damage
response. Nature 2006;444:756–60, http://dx.doi.org/10.1038/nature05236.
[151] Frame FM,  Pellacani D, Collins AT, Simms MS,  Mann VM,  Jones GD, et al.
HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br J
Cancer 2013;109:3023–33, http://dx.doi.org/10.1038/bjc.2013.691.
[152] Konopleva M,  Zhao S, Hu W,  Jiang S, Snell V, Weidner D, et al. The
anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute
to  chemoresistance of non-proliferating leukaemic CD34+ cells. Br J
Haematol 2002;118:521–34.
[153] Madjd Z, Mehrjerdi AZ, Shariﬁ AM,  Molanaei S, Shahzadi SZ, Asadi-Lari M.
CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2
in  breast tumours. Cancer Immun 2009;9:4.
[154] Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene
expression and chemoresistance of CD133+ cancer stem cells in
glioblastoma. Mol  Cancer 2006;5:67,
http://dx.doi.org/10.1186/1476-4598-5-67.
[155] Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, et al. Mechanistic
rationale for MCL1 inhibition during androgen deprivation therapy.
Oncotarget 2015;6:6105–22.
[156] Shervington A, Lu C. Expression of multidrug resistance genes in normal and
cancer stem cells. Cancer Invest 2008;26:535–42,
http://dx.doi.org/10.1080/07357900801904140.
[157] Brown MD,  Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ, et al.
Characterization of benign and malignant prostate epithelial Hoechst 33342
side  populations. Prostate 2007;67:1384–96,
http://dx.doi.org/10.1002/pros.20620.
[158] Drake JM,  Graham NA, Lee JK, Stoyanova T, Faltermeier CM,  Sud S, et al.
Metastatic castration-resistant prostate cancer reveals intrapatient
similarity and interpatient heterogeneity of therapeutic kinase targets. Proc
Natl Acad Sci U S A 2013;110:E4762–9,
http://dx.doi.org/10.1073/pnas.1319948110.[159] Aggarwal RR, Ryan CJ, Chan JM.  Insulin-like growth factor pathway: A link
between androgen deprivation therapy (ADT), insulin resistance, and
disease progression in patients with prostate cancer? Urol Oncol
2013;31:522–30, http://dx.doi.org/10.1016/j.urolonc.2011.05.001.
1  Cance
[177] Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen44 F.R. Santer et al. / Seminars in
[160] Harle LK, Maggio M,  Shahani S, Braga-Basaria M,  Basaria S. Endocrine
complications of androgen-deprivation therapy in men with prostate
cancer. Clin Adv Hematol Oncol 2006;4:
687–96.
[161] Feilotter HE, Nagai MA,  Boag AH, Eng C, Mulligan LM.  Analysis of PTEN and
the  10q23 region in primary prostate carcinomas. Oncogene
1998;16:1743–8, http://dx.doi.org/10.1038/sj.onc.1200205.
[162] Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-speciﬁc
deletion of the murine Pten tumor suppressor gene leads to metastatic
prostate cancer. Cancer Cell 2003;4:209–21,
http://dx.doi.org/10.1016/S1535-6108(03)00215-0.
[163] Mulholland DJ, Tran LM,  Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous
role of PTEN in regulating castration-resistant prostate cancer growth.
Cancer Cell 2011;19:792–804, http://dx.doi.org/10.1016/j.ccr.2011.05.006.
[164] Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I,
Rescigno P, et al. PTEN protein loss and clinical outcome from
castration-resistant prostate cancer treated with abiraterone acetate. Eur
Urol 2015;67:795–802, http://dx.doi.org/10.1016/j.eururo.2014.10.027.
[165] Jia S, Gao X, Lee SH, Maira S-M, Wu X, Stack EC, et al. Opposing effects of
androgen deprivation and targeted therapy on prostate cancer prevention.
Cancer Discov 2013;3:44–51,
http://dx.doi.org/10.1158/2159-8290.CD-12-0262.
[166] Kolenko V, Teper E, Kutikov A, Uzzo R. Zinc and zinc transporters in prostate
carcinogenesis. Nat Rev Urol 2013;10:219–26,
http://dx.doi.org/10.1038/nrurol.2013.43.
[167] Smith DJ, Jaggi M,  Zhang W,  Galich A, Du C, Sterrett SP, et al.
Metallothioneins and resistance to cisplatin and radiation in prostate cancer.
Urology 2006;67:1341–7, http://dx.doi.org/10.1016/j.urology.2005.12.032.
[168] Yamasaki M, Mimata H, Nomura T, Sato F. Metallothionein is up-regulated
under hypoxia and promotes the survival of human prostate cancer cells.
Oncol Rep 2007, http://dx.doi.org/10.3892/or.18.5.1145.r Biology 35 (2015) 133–144
[169] Sato M,  Bremner I. Oxygen free radicals and metallothionein. Free Radical
Biol Med  1993;14:325–37, http://dx.doi.org/10.1016/0891-
5849(93)90029-T.
[170] Otsuka T, Hamada A, Iguchi K, Usui S, Hirano K. Suppression of
metallothionein 3 gene expression by androgen in LNCaP prostate cancer
cells. Biomed Rep 2013;1:614–8, http://dx.doi.org/10.3892/br.2013.107.
[171] Cherian MG,  Apostolova MD.  Nuclear localization of metallothionein during
cell proliferation and differentiation. Cell Mol  Biol (Noisy-Le-Grand)
2000;46:347–56.
[172] Abdel-Mageed A, Agrawal KC. Antisense down-regulation of
metallothionein induces growth arrest and apoptosis in human breast
carcinoma cells. Cancer Gene Ther 1997;4:199–207.
[173] Notta F, Koropatnick DJ. Metallothioneins in drug resistance. In: Teicher BA,
editor. Cancer Drug Resistance. Totowa, NJ: Humana Press; 2006. p. 223–39.
[174] Mercader M, Bodner BK, Moser MT,  Kwon PS, Park ESY, Manecke RG, et al. T
cell inﬁltration of the prostate induced by androgen withdrawal in patients
with prostate cancer. PNAS 2001;98:14565–70,
http://dx.doi.org/10.1073/pnas.251140998.
[175] Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M,  Murphy GP.
Circulating levels of interleukin-6 in patients with hormone refractory
prostate cancer. Prostate 1999;41:127–33.
[176] Cavarretta IT, Neuwirt H, Zaki MH,  Steiner H, Hobisch A, Nemeth JA, et al.
Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine
in  a model of late stage prostate carcinoma. In: Li JJ, Li SA, Mohla S MD/PhD
HR, MD/PhD TM,  editors. Hormonal Carcinogenesis V. New York: Springer;
2008. p. 547–55.deprivation therapy plus docetaxel and estramustine versus androgen
deprivation therapy alone for high-risk localised prostate cancer (GETUG
12): A phase 3 randomised controlled trial. Lancet Oncol 2015,
http://dx.doi.org/10.1016/S1470-2045(15)00011-X.
